Leerink Partnrs Analysts Boost Earnings Estimates for RCKT

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Investment analysts at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for Rocket Pharmaceuticals in a note issued to investors on Wednesday, July 23rd. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings of ($0.49) per share for the quarter, up from their previous estimate of ($0.54). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for Rocket Pharmaceuticals’ Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($2.03) EPS, FY2026 earnings at ($2.13) EPS and FY2027 earnings at ($1.93) EPS.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02. During the same quarter in the prior year, the business earned ($0.66) EPS.

RCKT has been the topic of several other reports. Needham & Company LLC reiterated a “hold” rating on shares of Rocket Pharmaceuticals in a research note on Thursday, July 24th. Canaccord Genuity Group lowered their price target on Rocket Pharmaceuticals from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, July 25th. Wedbush reaffirmed an “outperform” rating and set a $32.00 price objective on shares of Rocket Pharmaceuticals in a research report on Friday, May 16th. Leerink Partners reiterated a “market perform” rating and issued a $8.00 price objective (down from $37.00) on shares of Rocket Pharmaceuticals in a report on Wednesday, May 28th. Finally, Bank of America restated a “neutral” rating and set a $4.00 target price (down previously from $9.00) on shares of Rocket Pharmaceuticals in a research note on Friday, July 25th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $17.87.

Rocket Pharmaceuticals Price Performance

Shares of RCKT opened at $3.01 on Monday. Rocket Pharmaceuticals has a twelve month low of $2.19 and a twelve month high of $25.18. The company has a market capitalization of $321.44 million, a P/E ratio of -1.14 and a beta of 0.67. The firm has a 50 day moving average of $3.25 and a 200 day moving average of $6.58. The company has a quick ratio of 9.19, a current ratio of 9.19 and a debt-to-equity ratio of 0.05.

Institutional Trading of Rocket Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its position in shares of Rocket Pharmaceuticals by 24.5% during the 4th quarter. Wellington Management Group LLP now owns 13,995,177 shares of the biotechnology company’s stock valued at $175,919,000 after acquiring an additional 2,753,033 shares during the period. Vanguard Group Inc. lifted its position in Rocket Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 6,617,784 shares of the biotechnology company’s stock valued at $44,141,000 after purchasing an additional 40,189 shares in the last quarter. Westfield Capital Management Co. LP lifted its position in Rocket Pharmaceuticals by 2.3% during the first quarter. Westfield Capital Management Co. LP now owns 4,820,701 shares of the biotechnology company’s stock valued at $32,154,000 after purchasing an additional 106,091 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Rocket Pharmaceuticals by 111.0% during the fourth quarter. Janus Henderson Group PLC now owns 4,004,039 shares of the biotechnology company’s stock valued at $50,343,000 after purchasing an additional 2,106,699 shares during the period. Finally, Suvretta Capital Management LLC bought a new stake in Rocket Pharmaceuticals during the fourth quarter valued at about $32,267,000. 98.39% of the stock is currently owned by institutional investors.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.